Dr. Qin Xu 徐沁
Chief Physician
Department of Gynecologic Oncology, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiotherapy and chemotherapy for cervical cancer, with a focus on 3D interstitial brachytherapy for advanced and recurrent cases.
Dr. Xu holds a medical doctorate and has over ten years of experience in gynecologic oncology. The doctor teaches at Fujian Medical University, leads a National Natural Science Foundation project, and has completed multiple provincial-level research projects. Dr. Xu has published 14 papers in international core journals with a total SCI score exceeding 50.
Name order: in Chinese the family name comes first (Xu Qin). Papers usually list the name as Qin Xu or Xu Q.
Selected publications
45 papers on PubMed matched by name and affiliation; 31 as first or senior author since 2016. Most recent first- or senior-author papers:
- Eur J Psychotraumatol, 2026 (senior author): Long-term impact of childhood exposure to interparental physical violence on cancer risk in adulthood: a prospective cohort study. PubMed 42592666
- PLoS One, 2026 (senior author): Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation. PubMed 42809552
- Transl Cancer Res, 2026 (senior author): A retrospective cohort study comparing long-term clinical outcomes between patients with and without neoadjuvant therapy in stage IB-IIB cervical cancer: a propensity score-matched study. PubMed 41969475
- Front Immunol, 2026 (senior author): PIK3CA mutation-induced immune microenvironment remodeling sensitizes cervical cancer to immunotherapy. PubMed 41958669
- J Transl Med, 2026 (senior author): SMC4/SMAD3/NF-κB axis drives cervical cancer progression and radioresistance via DNA damage repair and immune modulation. PubMed 41803949
- Cancer Discov, 2026 (first author): Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer. PubMed 41297028
- Cancer Control, 2026 (senior author): Survival and Treatment Patterns in Vulvar Paget's Disease: Evidence From SEER. PubMed 42133445
- Cancer Control, 2026 (senior author): The Prognosis of Patients With Large Cell Carcinoma of the Cervix: A Retrospective Study of the SEER Database and a Chinese Multi-Center Registry. PubMed 42118669
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion